

22.03.2019

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: *CAPLIPOINT*.

By NEAPS

Dear Sirs,

SUB-PRESS RELEASE - DISCLOSURE UNDER REGULATION 30 OF SEBI(LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015

We wish to inform exchanges that, Caplin Steriles Limited a Wholly Owned Subsidiary of Caplin Point Laboratories Ltd has received US Food and Drug Administration (US FDA) approval for Glycopyrrolate injection.

Please find the enclosed Press Release.

Kindly take the same on your records.

Thanking you,

Yours Faithfully,
For Caplin Point Laboratories Limited


Company Secretary
Enclosure : As above



PRESS RELEASE

**CAPLIN STERILES GETS USFDA APPROVAL
FOR GLYCOPYRROLATE INJECTION**

Chennai, Mar 22, 2018: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) announced that Caplin Steriles Limited (a Wholly Owned Subsidiary of Caplin Point Laboratories Ltd), has been granted final approval by the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Glycopyrrolate injection USP, 0.2mg/mL (in 1 mL, 2 mL, 5 mL and 20 mL vial presentations), a generic therapeutic equivalent version of Robinul from West-Ward Pharmaceuticals International Limited. Glycopyrrolate is an anticholinergic drug.

"We're happy to receive this nod from USFDA for Glycopyrrolate injection USP, which is the first ANDA approval for Caplin Steriles under our own name and it is the 4th approved ANDA from our facility. It's an important milestone in our journey in the regulated markets and we're working towards launching the product shortly in the US", said Mr. C.C.Parthipan, Chairman of Caplin Point Laboratories Ltd.

According to IQVIA™ (IMS Health), Glycopyrrolate had US sales data of approximately \$110.12 Million for the 12 month period ending December 2018. Caplin Steriles has developed and filed a total of 11 ANDAs, of which 7 are on its own (Caplin Steriles) and 4 with partners. We have 4 approvals so far of which three through partners and current approval is the first under our own name.

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state-of-the-art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has over 2,800 product approvals across the globe with another 250+ in the pipeline. The Company's Wholly Owned Subsidiary Caplin Steriles Ltd caters to the Regulated Markets for Injectable and Ophthalmic products.

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.





Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact :

Investor Relations Team at Caplin

Mr.Vinod Kumar (Company Secretary)

Tel: +91 44 24968000

investor@caplinpoint.net

Dikshita Jain

Christensen Investor Relations

Tel : +91 22 4215 0210

djain@christensenir.com

Registered Office

Narbhavi No. 3, Lakshmanan Street,
T Nagar, Chennai, Tamil Nadu, 600017

Telephone: 044-28156653

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: www.caplinpoint.net

